Syantra, Inc. Partners with Breast Cancer Foundation NZ
Syantra, Inc., a pioneering force in precision biotechnology dedicated to early cancer detection, has announced an exciting partnership with Breast Cancer Foundation NZ. This collaboration is a pivotal move to expand the reach of Syantra's innovative cancer detection platform, Onco-ID™, specifically its first test, Onco-ID Breast.
Opportunities in New Zealand's Healthcare Landscape
The New Zealand healthcare setting presents a unique landscape for Syantra's initiatives. With a diverse population and a supportive research community, New Zealand is ripe for advancements in cancer screening technologies. The nation also operates a national screening program for breast cancer, providing a ready-made avenue for clinical research.
Commitment to Advancing Patient Care
Rob Lozuk, CEO of Syantra, emphasized the significance of this partnership, stating, "This collaboration underscores Syantra's commitment to advancing patient care through rigorous clinical validation." By teaming up with the Breast Cancer Foundation NZ, Syantra aims to leverage its platform to boost real-world patient outcomes and offer new avenues for breast cancer detection.
Innovative Cancer Detection with Onco-ID
At the heart of this project is the Onco-ID platform, which relies on unique signals from the body’s immune system to identify active cancer presence. The technology is designed to detect subtle changes in normal bodily functions, allowing for identification of biological signals that would otherwise go unnoticed.
Innovating Equitable Solutions for Women
Hannah Holtkamp, PhD, the Innovation Development Manager at Breast Cancer Foundation NZ, expressed her enthusiasm for the partnership. "We value Syantra investing their resources to understand the unique needs of the New Zealand population. It's thrilling to witness Syantra’s progress in creating accessible screening options, striving together towards our common goal: ensuring no more deaths from breast cancer," she remarked.
About Syantra
Founded by a dynamic team based in Calgary with expertise in biomedical engineering and medicine, Syantra, Inc. is dedicated to transforming the landscape of cancer detection. Supported by prominent clinicians, the company is at the forefront of precision biotechnology, focusing on innovative solutions to change how cancer is detected and managed.
About Breast Cancer Foundation NZ
Breast Cancer Foundation NZ is a dedicated non-profit organization with a mission to drastically reduce breast cancer fatalities. Their efforts span across New Zealand, empowering patients, clinicians, and researchers alike. They advocate for early diagnosis, swift treatment, and rapid implementation of solutions, striving to achieve their vision of zero deaths from breast cancer.
Frequently Asked Questions
What is the focus of the partnership between Syantra and Breast Cancer Foundation NZ?
The partnership aims to expand the reach of Syantra's Onco-ID Breast platform to enhance early cancer detection in New Zealand.
What is Onco-ID?
Onco-ID is a pioneering cancer detection platform developed by Syantra that utilizes the body’s immune response to detect active cancer signatures.
Why is New Zealand a significant location for Syantra's initiative?
New Zealand offers a diverse population and an established national breast cancer screening program, making it ideal for testing innovative cancer detection solutions.
What does Breast Cancer Foundation NZ aim to achieve?
They aim to significantly reduce breast cancer mortality through early diagnosis and effective treatment strategies across communities in New Zealand.
How can I learn more about Syantra, Inc.?
You can learn more about Syantra, Inc. on their official website, where they provide details about their technology and mission in cancer detection.
